The World Health Organization (WHO) has issued a serious warning about the growing threat of antimicrobial resistance (AMR), cautioning that drug resistant infections could cause approximately 39 million deaths worldwide over the next 25 years if urgent action is not taken. In a new assessment released on November 16, 2026, the global health agency highlighted significant gaps in infection prevention, medical testing, responsible medicine use, and national healthcare policies. Although more countries have introduced strategies to address the problem, progress remains too slow to meet international targets. The warning raises concerns about the future effectiveness of antibiotics and other essential medicines, with potentially serious consequences for hospitals, patients, healthcare workers, and communities worldwide.
WHO Raises Concerns Over the Growing Antimicrobial Resistance Crisis
Antimicrobial resistance occurs when bacteria, viruses, fungi, and parasites develop the ability to survive medicines that were previously effective against them. As these microorganisms become resistant to available treatments, infections can become increasingly difficult to control. In severe cases, patients may face limited treatment options, longer hospital stays, serious complications, and an increased risk of death.
The WHO has described AMR as one of the major threats to global public health. The latest warning reflects growing concern that existing healthcare systems may struggle to manage infections that no longer respond to commonly prescribed medicines.
Speaking during the sixth annual Global Media Forum on AMR, Jean Pierre Nyemazi, acting director of the WHO’s antimicrobial resistance department, warned that resistance is widespread and threatens the future of modern medicine. He also pointed out that drug resistant infections have been taking lives for years without receiving the level of public attention needed to address the problem.
Unlike sudden disease outbreaks that generate immediate international headlines, antimicrobial resistance develops gradually. A patient may receive several courses of antibiotics without realizing that the underlying infection is becoming harder to treat. By the time resistance is identified, treatment options may already be limited.
39 Million Deaths Could Be Linked to Drug Resistant Infections
One of the most concerning findings highlighted by WHO officials is the projected human cost of antimicrobial resistance. If current trends continue, drug resistant infections could directly cause approximately 39 million deaths worldwide over the next 25 years.
The existing burden is already substantial. Estimates indicate that bacterial antimicrobial resistance directly caused approximately 1.14 million deaths in 2021 and was associated with around 4.7 million deaths globally. These figures demonstrate that AMR is not simply a future healthcare concern. It is already affecting patients across different regions and income groups.
The distinction between deaths directly caused by resistance and deaths associated with resistant infections is important. Some patients die because an infection cannot be treated effectively with available medicines. Others have resistant infections that contribute to serious complications alongside additional medical conditions.
The projected death toll also highlights the importance of acting before resistance becomes even more widespread. Better prevention, early diagnosis, appropriate prescribing, and stronger healthcare infrastructure could help reduce the number of people exposed to dangerous infections.
Global Progress Remains Too Slow Despite More National Action Plans
The WHO’s assessment of national efforts reveals an important difference between political commitments and practical implementation. An international review covering 183 countries found that 173 had developed national action plans to address antimicrobial resistance.
This represents considerable progress compared with 2017, when only 79 countries reported having such plans. However, the existence of a national strategy does not automatically mean that healthcare facilities have the funding, staff, equipment, and monitoring systems required to implement it.
According to the latest assessment, only 42 countries reported having AMR action plans that were financed, implemented, and monitored. This gap is particularly concerning because successful resistance control requires consistent action across hospitals, laboratories, pharmacies, agricultural systems, and public health institutions.
National governments must therefore move beyond announcing strategies and focus on delivering practical improvements. Without adequate financial resources and measurable progress, even well designed policies may have limited effects.
Antibiotic Resistance Is Threatening Routine Medical Treatment
Antibiotics have transformed modern healthcare by making many previously dangerous bacterial infections treatable. They also support medical procedures that depend on effective infection control, including major surgery, cancer treatment, organ transplantation, and childbirth related care.
However, rising antimicrobial resistance could weaken these medical protections. When bacteria become resistant to available antibiotics, doctors may have to use alternative treatments that are less effective, more expensive, or associated with additional side effects.
Why Hospitals Face Serious Risks
Hospitals are particularly vulnerable because patients with serious illnesses, weakened immune systems, or recent surgical procedures may already face an increased risk of infection. Resistant bacteria can spread between patients, healthcare workers, medical equipment, and contaminated surfaces when infection prevention measures are inadequate.
Common infections affecting the bloodstream, urinary tract, lungs, and surgical wounds can become more complicated when standard antibiotics no longer work. Patients may require additional laboratory testing, longer treatment periods, and specialized medical care.
People receiving chemotherapy or managing chronic illnesses also face additional concerns. An infection that might otherwise respond to routine treatment can become a serious medical complication when available medicines are ineffective.
Childbirth and Surgery Could Become More Dangerous
The consequences extend beyond patients already receiving intensive medical treatment. Routine surgical procedures and childbirth depend on reliable infection prevention and effective medicines when infections occur.
If antibiotic resistance continues to increase, medical professionals could face greater difficulties treating infections following surgery or pregnancy related complications. This would create additional pressure on healthcare facilities and potentially increase treatment costs for patients and families.
Protecting the effectiveness of existing antibiotics is therefore essential to maintaining the safety of medical procedures that millions of people depend on every year.
Weak Diagnostic Systems Make Treatment More Difficult
One of the major problems identified by WHO officials is the lack of sufficient diagnostic testing in many countries. Laboratory testing helps doctors identify the microorganisms responsible for an infection and determine which medicines are most likely to work.
Without reliable testing, healthcare professionals may have to begin treatment without knowing whether the infection is resistant to commonly prescribed antibiotics. This uncertainty can lead to inappropriate prescribing, delayed treatment, and unnecessary exposure to medicines.
The latest global surveillance findings indicate that approximately one in every six laboratory confirmed bacterial infections reported to WHO in 2023 was resistant to antibiotics used to treat it.
The agency has also highlighted major differences in laboratory capacity between countries. Although 131 countries reported having reference laboratories capable of testing resistance in common bacteria, only 66 could test for both bacterial and fungal resistance. Just 21 countries combined information about antimicrobial use with resistance surveillance data.
These weaknesses make it harder for governments to identify emerging threats, monitor changes in resistance patterns, and develop effective national responses.
WHO Introduces New Tools to Improve Medical Testing
To address diagnostic weaknesses, the WHO announced two new resources designed to help countries improve laboratory capabilities and strengthen infection diagnosis.
The first resource establishes the diagnostic tests that should be available at different levels of healthcare, ranging from primary care centers to larger referral hospitals. This approach is intended to help countries identify gaps in their medical testing infrastructure and determine where additional investment is needed.
The second resource brings together 73 laboratory procedures covering important stages of the diagnostic process. These include sample collection, identification of disease causing microorganisms, and antibiotic susceptibility testing.
Such testing can help medical professionals determine whether a particular medicine is likely to be effective against an identified infection. Better access to laboratory services could also reduce unnecessary antibiotic prescriptions and improve treatment decisions.
However, introducing diagnostic guidelines is only one part of the solution. Countries will also need trained laboratory professionals, reliable equipment, adequate funding, and effective systems for sharing medical information.
Misuse and Overuse of Antibiotics Are Accelerating Resistance
The misuse and overuse of antimicrobial medicines are among the major factors contributing to the spread of resistance. Antibiotics are essential for treating bacterial infections, but they do not work against viral illnesses such as influenza and the common cold.
Using antibiotics when they are not medically necessary exposes bacteria to medicines without providing the intended treatment benefit. Over time, this can encourage resistant microorganisms to survive and multiply.
Other contributing factors include inappropriate prescribing, access to medicines without proper medical guidance, inadequate infection control, and the use of antimicrobial products in animal health and food production.
Public awareness is therefore an essential part of the global response. Patients should avoid taking antibiotics without appropriate medical advice, should not use leftover prescriptions for unrelated illnesses, and should follow their healthcare professional’s instructions.
Healthcare providers also have an important responsibility to prescribe antimicrobial medicines carefully, select appropriate treatments, and review prescriptions when laboratory results become available.
Why Infection Prevention Must Become a Global Priority
Preventing infections is one of the most effective ways to reduce the need for antimicrobial medicines. When fewer people become infected, fewer require treatment, reducing opportunities for resistant microorganisms to spread.
Basic public health measures can make a meaningful difference. Access to clean water, proper sanitation, hand hygiene, vaccination, safe food handling, and effective hospital infection control all contribute to reducing infection rates.
However, the WHO assessment indicates that implementation remains inadequate. Only 69 countries, representing approximately 38 percent of those surveyed, had implemented infection prevention and control programs nationwide.
This falls considerably short of the international target of 90 percent by 2030. The gap demonstrates why governments must prioritize practical healthcare improvements rather than relying exclusively on awareness campaigns and policy announcements.
Antimicrobial Resistance Requires a One Health Approach
AMR cannot be addressed through hospitals and human healthcare systems alone. Resistant microorganisms can circulate between people, animals, food production systems, and the natural environment.
This connection is commonly described as the One Health approach, which recognizes that human health, animal health, and environmental conditions are closely connected.
In agriculture, the responsible use of antimicrobial medicines is important for limiting the development and spread of resistance. Veterinary professionals and agricultural producers must follow appropriate treatment practices and avoid unnecessary antimicrobial exposure in animals.
Environmental management also matters. Poorly treated wastewater from healthcare facilities, pharmaceutical manufacturing, and agricultural operations can contribute to the spread of resistant microorganisms and antimicrobial residues.
International cooperation between health authorities, agricultural organizations, environmental agencies, and veterinary services is therefore necessary to manage the problem effectively.
What Governments Must Do Before the 2030 Global Targets
Countries have already agreed to international targets designed to reduce the health burden of antimicrobial resistance by 2030. However, the latest WHO findings suggest that many governments are not moving quickly enough to achieve them.
Several areas require immediate attention:
- Increase healthcare funding: Provide sufficient resources to implement national AMR strategies and maintain essential public health programs.
- Improve laboratory testing: Expand access to reliable diagnostic services and antimicrobial susceptibility testing.
- Strengthen infection prevention: Improve sanitation, vaccination coverage, hospital hygiene, and infection control practices.
- Promote responsible prescribing: Reduce unnecessary antimicrobial use in human and animal healthcare.
- Expand surveillance: Improve national systems for monitoring resistant infections and antimicrobial consumption.
- Support medical research: Encourage the development of new antibiotics, diagnostic technologies, and alternative treatment approaches.
These measures require sustained cooperation between governments, international organizations, pharmaceutical companies, healthcare professionals, and local communities.
Developing Countries Face Additional Challenges
Low and middle income countries may face particularly serious difficulties because of limited healthcare funding, inadequate laboratory facilities, shortages of trained medical professionals, and unequal access to essential medicines.
In some communities, patients may struggle to obtain appropriate diagnostic testing or reach healthcare facilities. At the same time, weak medicine regulation and limited public awareness can contribute to inappropriate antibiotic use.
Improving access to effective treatment is just as important as restricting unnecessary medicine consumption. Patients should not be left without appropriate antibiotics when they genuinely need them. The objective is to ensure that effective medicines remain accessible while reducing practices that accelerate resistance.
International financial support, technology sharing, laboratory training, and stronger public health infrastructure can help countries develop more effective responses.
What the WHO Warning Means for the Future of Global Healthcare
The WHO’s latest warning highlights a serious challenge for healthcare systems worldwide. Antimicrobial resistance is already responsible for substantial illness and loss of life, while projections suggest that the consequences could become considerably worse over the coming decades.
Nevertheless, the situation is not beyond control. Better infection prevention, responsible prescribing, reliable diagnostic testing, and stronger national policies can reduce the spread of resistant microorganisms and protect existing medical treatments.
Readers can follow official developments, global surveillance findings, and recommended public health measures through the World Health Organization’s official website.
The central message from the November 16 warning is clear: antimicrobial resistance requires action now, not after treatment options have become even more limited. Protecting the effectiveness of antibiotics and other essential medicines is a shared responsibility involving governments, medical professionals, pharmaceutical researchers, agricultural producers, and ordinary citizens.
The decisions made during the coming years will influence how effectively future generations can treat infections, perform routine medical procedures, and respond to emerging diseases. Preserving the power of modern medicine will depend on whether the international community can turn its growing awareness of AMR into consistent, practical action.

